RU-2026103587-A - TREATMENT METHODS FOR PRIMARY BILIARY CHOLANGITIS

Inventors

• МИЛЛЕР Бенджамин
• ЗЕЙН Клаудия
• ШУ Цзяньфэнь
• АЛЛАН Ричард
• АНТУНЕШ Нуну

Assignees

• ИПСЕН ФАРМА

Dates

Publication Date

20260504

Application Date

20240722

Priority Date

20230822

Claims (20)

1. 1. The use of elafibranor for the treatment of primary biliary cholangitis (PBC) in a subject with PBC and liver cirrhosis.
2. 2. The use of paragraph 1, where the subject has a Child-Pugh score of A or a Child-Pugh score of B.
3. 3. The use of paragraph 1, where the subject has a Child-Pugh score of A.
4. 4. Use according to paragraph 1 or 2, where the subject has a Child-Pugh score of B.
5. 5. The use according to claim 1, wherein the subject has moderate liver dysfunction.
6. 6. Use according to any of paragraphs 2, 4 or 5, where the subject is at risk of developing decompensated liver cirrhosis.
7. 7. Use according to any one of claims 1-6, where the subject is at risk of progression of liver cirrhosis.
8. 8. Use according to any of paragraphs 1-7, where the subject is at risk of developing portal hypertension.
9. 9. Use of elafibranor to prevent hepatic decompensation in a subject with PBC and liver cirrhosis.
10. 10. Use according to paragraph 9, where the subject is at risk of developing decompensated liver cirrhosis.
11. 11. Use according to item 9 or 10, where the subject has a Child-Pugh score of A or has a Child-Pugh score of B.
12. 12. Use of elafibranor for the prevention of portal hypertension in a subject with PBC and liver cirrhosis.
13. 13. Use according to paragraph 12, where the subject is at risk of developing portal hypertension.
14. 14. Use according to paragraph 12 or 13, where the subject has a Child-Pugh score of A or has a Child-Pugh score of B.
15. 15. Use of elafibranor to prevent liver transplantation in a subject with PBC and liver cirrhosis.
16. 16. Use according to paragraph 15, where the subject is at risk for liver transplantation.
17. 17. Use according to paragraph 15 or 16, where the subject has a Child-Pugh score of A or has a Child-Pugh score of B.
18. 18. Use of elafibranor to prevent progression to liver cirrhosis in a subject with PBC and without liver cirrhosis.
19. 19. Use according to paragraph 18, where the subject is at risk of developing liver cirrhosis.
20. 20. The use according to any one of claims 1-19, wherein the subject has at least a partial response to UDCA (ursodeoxycholic acid).